Skip to main content

Topic

ANDA Litigation

15 published works

  1. ANDVA Advisor Blog

    IRS Treatment of Litigation Costs in ANDA Cases

    By Christopher Johnson

    The Third Circuit Court of Appeals will decide whether the IRS can force Mylan (and by extension other ANDA filers) to treat a) legal expenses to prepare notice letters and…

  2. Harness Dickey Blog

    Patent Venue Construed Strictly, Even in ANDA Litigation

    By Todd

    In Celgene Corp. v. Mylan Pharmaceutics Inc., [2021-1154] (November 5, 2021) the Federal Circuit affirmed the dismissal of a patent infringement action against defendants, MPI and Mylan Inc., for improper…

  3. Prosecution First Blog

    Patentee’s Success Story in a Hatch-Waxman Litigation Case

    By Publisher

    In Tris Pharma, Inc. v. Actavis Labs. FL, Inc., 2020 WL 7028456, at *1 (D. Del. Nov. 30, 2020), the district court for the District of Delaware, on remand from…

  4. Commercial Litigation Update

    Restrictions on Venue in Hatch-Waxman Litigation

    By Theodora McCormick

    Since the enactment of the Hatch-Waxman Act in 1984, courts have held that brand companies can sue generics wherever they plan on making sales, which is everywhere in the U.S.…

  5. Big Molecule Watch

    Upcoming Webinar: Navigating Hatch-Waxman and Biologic Litigation Amid the Coronavirus Pandemic

    By Big Molecule Watch

    On Thursday, April 23rd, Goodwin will be hosting a webinar, Navigating Hatch-Waxman and Biologic Litigation Amid the Coronavirus Pandemic. Join Goodwin experts, John Bennett, Elaine Blais, Srikanth Reddy and Daryl…

  6. BioLoquitur

    Innovation in Hatch-Waxman and ANDA Litigation

    By Parithosh K. Tungaturthi, Ph.D.

    The Hatch-Waxman Act was enacted in 1984 to address two main congressional goals: (1) to encourage innovation in pharmaceutical research and development; and (2) to help generic drugs reach the…

  7. BioLoquitur

    Now Available! Seyfarth Shaw’s Hatch-Waxman and Biosimilars Litigation: 2017 Year-in-Review

    By Parithosh K. Tungaturthi, Ph.D., Dean L. Fanelli, Ph.D., Thomas A. Haag, Ph.D., Jamaica Szeliga

    Seyfarth Shaw Offers Hatch-Waxman And Biosimilars Litigation: 2017 Year-in-Review Today’s rapid scientific and technological advances demand not only a thorough understanding of the complex technology, but also a meticulous application…

  8. Delaware Intellectual Property Litigation

    Judge Sleet Denies Macleods Defendants’ Motion for Judgment on the Pleadings in ANDA Action

    By Fox Rothschild LLP

    By Memorandum Order entered by The Honorable Gregory M. Sleet in Amgen Inc. v. Macleods Pharmaceuticals, Ltd., Civil Action No. 17-817-GMS (D.Del. December 19, 2017) (consolidated), the Court denied the…

  9. Delaware Intellectual Property Litigation

    Chief Judge Stark Denies Defendants’ Motion for Reargument of Court’s Order Holding Defendants Liable for Costs of ANDA Litigation Going Forward Under Certain Conditions

    By Fox Rothschild LLP

    By Memorandum Order entered by The Honorable Leonard P. Stark in UCB, Inc., et al. v. Watson Laboratories, Inc. et al., Civil Action No. 14-1083-LPS-SRF (D.Del., May 19, 2017), the…

  10. Delaware Intellectual Property Litigation

    Judge Andrews Grants in Part Teva’s Motion to Dismiss ANDA Complaint

    By Fox Rothschild LLP

    By Memorandum Opinion entered by The Honorable Richard G. Andrews in Endo Pharmaceuticals Inc. et al. v. Actavis Inc. et al., Civil Action No. 14-1381-RGA (D.Del. February 8, 2017), the…